A randomized trial of glutamine and antioxidant supplementation in critically ill patients

This study is registered at Clinicaltrials.gov.
Identification number NCT00133978

September 21st, 2007
# Table of Contents

Study Contacts ......................................................................................................3  
Dietitian Responsibilities .......................................................................................4  
Study Duration ......................................................................................................4  
Data Collection ......................................................................................................5  
  Baseline Nutrition .................................................................................................5  
  Daily Nutrition Data ................................................................................................7  
  Formula Taxonomy ..................................................................................................9  
Other Vitamins, Minerals and Supplements ..........................................................12  
Optimizing Enteral Nutrition and Study Supplements .........................................12  
Enteral Feeding Protocol .......................................................................................13  
Study Supplements & Renal Dysfunction .............................................................14  
Checklist for Daily Data collection .....................................................................18  

---

September 21st, 2007
### Study Contacts

- **Principal Investigator**
  
  Dr Daren Heyland  
  Kingston General Hospital  
  Angada 4, 76 Stuart Street  
  Kingston ON K7L 2V7  
  Tel: 613-549-6666 ext. 3339  
  Fax: 613-548-2428  
  Email: dkh2@queensu.ca

- **Project Leader**
  
  Rupinder Dhaliwal, RD  
  Kingston General Hospital  
  Angada 4, 76 Stuart Street  
  Kingston ON K7L 2V7  
  Phone 613-549-6666 ext 3830  
  Cell Phone: 613-484-3830  
  Fax: 613-548-2428  
  Email dhaliwar@kgh.kari.net
Dietitian Responsibilities

The ICU dietitian at each participating site will ensure that the patients enrolled to the REDOXS© study receive adequate enteral nutrition (or parenteral nutrition if enteral route is contra-indicated) as recommended by the Canadian Clinical Practice Guidelines for Nutrition Support (Heyland, Dhaliwal, Drover et al JPEN 2003. For updated versions, refer to www.criticalcarenutrition.com).

The dietitian will also assist the Study Coordinator in collecting data on the delivery of nutrition in these patients.

The dietitian will work in collaboration with the STUDY COORDINATOR to minimize the interruptions to the study supplements.

Please refer to the “Administration of Study Supplements Manual”, for details on the study supplements.

Study Duration

The study period is from ICU admission until day 30 unless ICU discharge (actual) or death occurs before day 30. All daily data collection including the data on enteral and parenteral nutrition will continue for this duration unless enteral or parenteral nutrition has been discontinued permanently and the patient has progressed to oral intake before day 30.

The study supplements will be provided for a maximum of 28 days from randomization, unless ICU discharge/death occurs before this. Data collection pertaining to the study supplements will continue for this duration.

THE DURATION OF THE STUDY SUPPLEMENTS SHOULD NOT EXCEED A TOTAL OF 28 DAYS. Study supplements will be discontinued in the event that the patient is discharged from ICU or dies before 28 days (exception: patients with ICU stay < 5 days and transferred to ward; duration of study supplements should be 5 days in total = 120 hours).
Data Collection

The collection of nutrition data will assist the dietitian in determining whether the REDOXS® patients are being fed adequately via enteral (or parenteral nutrition). The data may be collected retrospectively, however collecting data on a daily basis will allow the dietitian to identify and resolve gaps in current practice in a timely manner.

The dietitian will not be entering any data in to the web based data capture system, but will be providing the data to the Study Coordinator who is responsible for entering the data. Web shots are shown here to illustrate the type of data that needs to be collected.

It is recommended that the dietitian work closely with the Study Coordinator to determine the best approach for collecting the data (worksheets/daily checklists, etc). A sample check list is provided (see page 18).

Baseline Nutrition

Prescribed Energy and Protein Intake
This will need to be calculated by the dietitian once at baseline as below:

- The prescribed energy and protein intake is the kilocalories and grams of protein provided by the goal regimen (i.e. maximum rate/volume determined at the initial assessment) for EN/PN according to the dietitian’s recommendation.
  - For eg. If the dietitian recommends a starting rate of 25 ml/hr on day 1 with a final rate of 75 ml/hr by day 3, calculate the calories and protein that the final rate = 75ml/hr X 24 would provide.

- Include calories from protein.

- If the patient is on enteral nutrition and parenteral nutrition at the same time, the prescribed energy and protein intake will still be the FINAL amount as assessed by the dietitian.

- If the prescription changes over the days of observation, calculate the average prescribed calories and protein.

Enteral Nutrition/Parenteral Nutrition Start and Stop Dates
The Study Coordinator is responsible for collecting this data but the dietitian is encouraged to work with the Study Coordinator to determine the best approach for collecting this data.

Enteral Nutrition
- Indicate if enteral nutrition was started prior to ICU admission and continued in ICU, “Yes” or “No” or whether it was never received in ICU.
  - If Yes, use ICU admission date/time as enteral nutrition start date/time.
  - If No, record the date and time enteral nutrition was started in ICU.
- Record the date and time that enteral nutrition was discontinued (permanently) in ICU.
  - If enteral nutrition is continued beyond ICU discharge, record the ICU discharge as the date and time enteral nutrition was stopped even if the study supplements are continued beyond ICU discharge (in patients that are in ICU < 5 days).

**Parenteral Nutrition**

- Indicate if parenteral nutrition was started prior to ICU admission and continued in ICU, “Yes” or “No” or whether it was never received in ICU.
  - If Yes, use ICU admission date/time as parenteral nutrition start date/time.
  - If No, record the date and time parenteral nutrition was started in ICU.
- Record the date and time that parenteral nutrition was discontinued (permanently) in ICU.
  - If parenteral nutrition is continued beyond ICU discharge, record the ICU discharge as the date and time enteral nutrition was stopped even if the study supplements are continued beyond ICU discharge (in patients that are in ICU < 5 days).

---

**Webshot of Baseline Nutrition**

[Image of a webshot showing baseline nutrition data]
Daily Nutrition Data

This page is for recording daily data pertaining to the delivery of enteral or parenteral nutrition and is separate from the Study Supplement Forms.

The data collection for the delivery of enteral and parenteral nutrition is from study Day 1 until study Day 30. The data collection for the study supplements is from study Day 1 onwards for a maximum of 28 days from randomization.

Study Day 1 is from ICU admission to the end of your 24 hr flowsheet. Study Day 2 and subsequent days are the 24 hr period according to your flowsheet.

Enteral Nutrition/Parenteral Nutrition

Total Energy Intake
This will need to be calculated by the dietitian daily as follows:
- include calories from protein
- include calories from other supplements.
- include calories from propofol if continuous infusion ≥ 6 hrs. Do NOT include intermittent doses of propofol.
- do NOT include calories from IV solutions.
- do NOT include calories from the study supplements.

Total Protein Intake
This will need to be calculated by the dietitian daily as follows:
- include protein from supplements.
- do NOT include the grams of protein from the study supplements.

- If patient is on a combination of Enteral Nutrition and Parenteral Nutrition, please calculate the calories received from each separately.

If the patient is not receiving enteral or parenteral nutrition but is receiving propofol, you do NOT need to record the calories from propofol.

The dietitian is encouraged to assist the Study Coordinator by collecting the following data.

Type of Enteral Formula
Using the taxonomy on next page, please record enteral formula(s) received.
- If formula not listed on this taxonomy, choose other and write down the name of the formula
- You may record up to 3 formulas per day. In the event that the patient receives more than 3 formulas, record the 3 that provided the largest volumes.
Enteral Nutrition interrupted due to Feeding Intolerance

If patient is on enteral nutrition, indicate Yes or No if enteral nutrition was ever interrupted due to feeding intolerance.

- An interruption in enteral feeding is defined as a reduction in the rate of delivering the feed or stopping the feed.
- Feeding intolerance is defined as the presence of any one of the following:
  - High gastric residual volumes
  - Emesis
  - Aspiration of enteral nutrition

Enteral Nutrition interrupted due to fluid concerns/elevated urea

If enteral nutrition is interrupted due to high urea or fluids concerns, indicate Yes or No. If yes, provide an explanation.
## Formula Taxonomy

<table>
<thead>
<tr>
<th>Formula Name</th>
<th>Formula Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>MEAD JOHNSON: Portagen</td>
<td>NOVARTIS: Vivonex TEN</td>
</tr>
<tr>
<td>NESTLE: Peptamen with Prebio 1</td>
<td>NOVARTIS: Vivonex Plus</td>
</tr>
<tr>
<td>NESTLE: Peptamen</td>
<td>NOVARTIS: Supplements- Instant Protein Powder</td>
</tr>
<tr>
<td>NESTLE: Peptamen 1.5</td>
<td>NOVARTIS: Supplements - Microlipid</td>
</tr>
<tr>
<td>NESTLE: Peptamen VHP</td>
<td>NOVARTIS: Supplements - MCT oil</td>
</tr>
<tr>
<td>NESTLE: Peptamen AF</td>
<td>NOVARTIS: Supplements-Resource Glutasolve</td>
</tr>
<tr>
<td>NESTLE: Nutren 2.0</td>
<td>ROSS: Jevity 1 kcal</td>
</tr>
<tr>
<td>NESTLE: Nutren 1.5</td>
<td>ROSS: Jevity 1.2 kcal</td>
</tr>
<tr>
<td>NESTLE: Nutren VHP</td>
<td>ROSS: Osmolite HN Plus</td>
</tr>
<tr>
<td>NESTLE: Nutren VHP fibre</td>
<td>ROSS: Osmolite HN</td>
</tr>
<tr>
<td>NESTLE: Nutren Fibre with Prebio 1</td>
<td>ROSS: Promote</td>
</tr>
<tr>
<td>NESTLE: Nutren Fibre with Prebio 1.5</td>
<td>ROSS: Glucerna</td>
</tr>
<tr>
<td>NESTLE: Nutrihep</td>
<td>ROSS: Nepro</td>
</tr>
<tr>
<td>NESTLE: Supplements - Caloreen</td>
<td>ROSS: Suplена</td>
</tr>
<tr>
<td>NOVARTIS: Compleat</td>
<td>ROSS: Pulmocare</td>
</tr>
<tr>
<td>NOVARTIS: Impact</td>
<td>ROSS: Perative</td>
</tr>
<tr>
<td>NOVARTIS: Impact 1.5</td>
<td>ROSS: Vital HN</td>
</tr>
<tr>
<td>NOVARTIS: Isosource HN</td>
<td>ROSS: TWO Cal HN</td>
</tr>
<tr>
<td>NOVARTIS: Isosource HN with fibre</td>
<td>ROSS: Oxepa</td>
</tr>
<tr>
<td>NOVARTIS: Isosource VHN</td>
<td>ROSS: Optimalental</td>
</tr>
<tr>
<td>NOVARTIS: Isosource 1.5</td>
<td>ROSS: Ensure</td>
</tr>
<tr>
<td>NOVARTIS: Novasource Renal</td>
<td>ROSS: Ensure High Protein</td>
</tr>
<tr>
<td>NOVARTIS: Peptinex</td>
<td>ROSS: Ensure Plus</td>
</tr>
<tr>
<td>NOVARTIS: Peptinex DT</td>
<td>ROSS: Ensure Fibre</td>
</tr>
<tr>
<td>NOVARTIS: Resource 2.0</td>
<td>ROSS: Supplements -Polycose powder</td>
</tr>
<tr>
<td>NOVARTIS: Resource Plus</td>
<td>ROSS: Supplements -Polycose Liquid</td>
</tr>
<tr>
<td>NOVARTIS: Resource Standard</td>
<td>Hormel Health: Immun-Aid</td>
</tr>
<tr>
<td>NOVARTIS: Resource Diabetic</td>
<td>Hormel Health: Hepatic-Aid</td>
</tr>
<tr>
<td>NOVARTIS: Tolerex</td>
<td>Other:</td>
</tr>
<tr>
<td>NOVARTIS: Trauma-cal</td>
<td></td>
</tr>
</tbody>
</table>

September 21st, 2007
Parenteral Lipids
If on parenteral nutrition, indicate with a “Yes” or “No” if patient received lipids.
  ▪ If yes, use the taxonomy provided to select the type of lipid (see below).

<table>
<thead>
<tr>
<th>Type of lipids</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Soybean oil based (LCTs)</td>
</tr>
<tr>
<td>2. MCT/LCT physical mixture</td>
</tr>
<tr>
<td>3. MCT/LCT structured form</td>
</tr>
<tr>
<td>4. Olive Oil based</td>
</tr>
<tr>
<td>5. Fish Oil based (10-20% of total lipid emulsion)</td>
</tr>
<tr>
<td>6. Mixture of soy oil, MCTs, and fish oil</td>
</tr>
<tr>
<td>7. Mixture of soy oil, MCTs, olive oil, and fish oil (SMOF)</td>
</tr>
<tr>
<td>8. Other, specify ____________</td>
</tr>
</tbody>
</table>

Parenteral Nutrition interrupted due to fluid concerns/elevated urea
If parenteral nutrition is interrupted due to high urea or fluids concerns, indicate Yes or No. If yes, provide an explanation.

The dietitian is to forward all the nutrition related data collected for each REDOXS© patient to the Study Coordinator in a timely manner. The Study Coordinator will enter this on the web based data capture system.
### Webshot of Daily Nutrition Data

#### Daily Nutrition

<table>
<thead>
<tr>
<th>Day</th>
<th>Date</th>
<th>Enteral received</th>
<th>Enteral energy</th>
<th>Enteral protein</th>
<th>Parenteral received</th>
<th>Parenteral energy</th>
<th>Parenteral protein</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>04/05/2007</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Enteral Nutrition**

- Did patient receive enteral nutrition today? [ ] YES [ ] NO
- Total energy intake: ___ (kcal)
- Total protein intake: ___ (g)

- Formula (may select up to 3)
  - MEAD JOHNSON: Pentagen
  - NESTLE: Peptamen with Fries 1
  - NESTLE: Peptamen
  - NESTLE: Peptamen 1.5

- EN interrupted due to intolerance? [ ] YES [ ] NO
  (either high gastric residual volumes or emesis or aspiration of formula)

- EN interrupted due to high urea or fluid concerns? [ ] YES [ ] NO

**Parenteral Nutrition**

- Did patient receive parenteral nutrition today? [ ] YES [ ] NO
- Total energy intake: ___ (kcal)
- Total protein intake: ___ (g)

- Type of Lipids
- PN interrupted due to high urea or fluid concerns? [ ] YES [ ] NO

**Comments:**

---

**September 21st, 2007**
Other Vitamins, Minerals, Supplements

Patients that are enrolled in this study should NOT to be on enteral formulas, parenteral solutions or supplements that have elevated levels of glutamine, antioxidants or selenium, vitamin A,C,E, beta-carotene, zinc or arginine. The patient enrolled in the study should NOT be placed on the following:

- Vivonex Plus/T.E.N
- Oxepa
- Optimental
- Impact/Impact 1.5
- Perative
- Peptamen AF
- Probiotics
- Glutamine supplements

The following are exceptions and are allowed:

- Thiamine, folic acid
- Standard multivitamin/mineral preparations (maximum of 5 mg zinc)
- Standard amounts of vitamins and minerals already present in enteral or parenteral solutions (maximum of 5 mg zinc and 60 µgms selenium).
- Vitamin K

In patients on long term parenteral nutrition, supplementation may be necessary and can be started after notifying the Project Leader.

If the patient has been on any of these formulas/supplements prior to enrolment in the study (either at home or in a hospital), these should be discontinued once the patient is enrolled.

Optimizing Enteral Nutrition and Study Supplements

- To optimize the delivery of enteral nutrition and study supplements in patients enrolled to the REDOXS© study, it is recommended that the following strategies be utilized:
  - Elevate the head of the bed
  - Start motility agents
  - Start small bowel feeding

- Refer to Enteral Feeding Protocol on next page for more details on how to utilize these strategies in a step-wise manner.

- In the event that enteral feeds are poorly tolerated, you may hold the enteral feeds as per your usual practice, however, DO NOT stop the study supplements. The study supplements are nutrients, and it is safe to deliver these small amounts regardless of whether enteral feeds are tolerated or not.
Enteral Feeding Protocol

Start Study Supplements
(once patient resuscitated and nasogastric tube in place)
Start Enteral Feeds per Clinical Practice Guidelines for Nutrition Support*

Elevate HOB to 45 degrees if possible

If this is the 1st GRV > 250 ml:
1) Refeed GRV to 400ml max
   and discard the rest
2) Start Maxeran 10mg IV q 6 hrs
3) Continue with STUDY SUPPLEMENTS
   and/or Enteral Feeds
4) Continue with checking GRV q 4hrs

Is this a rechecked residual that is > 250 mls?

YES

Check GRV q 4 hrs
(Only if gastric feeding)
Is the GRV > 250 mls?

YES

1) Refeed gastric residual
2) Continue with STUDY SUPPLEMENTS/Enteral Feeds

NO

1) Refeed gastric residual
2) Continue with STUDY SUPPLEMENTS/Enteral Feeds

NO

STOP STUDY SUPPLEMENTS/Enteral Feeds IF:
Patient develops:
- bowel obstruction
- bowel perforation

WATER FLUSHES:
Flush tube with at least 10 mls of sterile water:
-q4hrs during feedings
-after aspiration for GRV
-before and after meds

BLOCKED TUBE:
Pancrealipase 8000 units mixed with crushed Na Bicarb 500mg in 5ml warm water prn

Study Supplements in Renal Dysfunction

Since the study supplements contain above average amounts of protein (could range from 0-90 gms/day) and require 750 mls fluid/day, decisions about altering the management of the patient with respect to fluid, dialysis, type of enteral (or parenteral) nutrition will need to be made.

If the patient has renal failure, has an elevated urea of concern and is not going to be dialyzed, refer to Appendix II below for more details on specific questions relating to renal dysfunction.

Appendix II
Algorithm for Elevated Urea in Patients with Renal Disease

1. I am about to start the study supplements in a patient with existing renal dysfunction (elevated Creatinine, either acutely or chronically, particularly if they meet the criteria for renal dysfunction listed on the inclusion criteria, is there anything special I should do?
   Response: The study solutions contain trivial amounts of K+ but do contain above average amounts of protein (the protein composition could range from 0-90 gms of protein/day) and will require 750 ml/day of fluid to administer the study nutrients. Therefore, at the outset of starting the study supplements in patients with renal dysfunction, we recommend you concentrate all IV infusions and use concentrated, lower protein enteral feeding products, like Nepro, Suplena, Novasource Renal, etc. If after the first few days there are no significant elevations in urea or fluid concerns, you may consider switching to a standard enteral formula.

2. In patients with pre-existing renal dysfunction (either acute or chronic that receive study supplements containing high dose glutamine, the urea may rise disproportionately to the serum Creatinine. The patient does not have a standard indication for dialysis. How safe is this and what should be done about it?
   Response: We know the following:
   i. Glutamine is associated with a potential survival benefit in critically ill patients (1).
   ii. Doses of glutamine similar to or higher than what we are prescribing in this study are described as “safe and well tolerated” (2,3). The observed benefits of glutamine are observed in patients despite high urea levels (4).
   iii. High dose glutamine is associated with no worsening of renal function or SOFA scores (composite organ function) and lower levels of markers of oxidative stress (preliminary results of dosing study).
   iv. High dose glutamine and antioxidants were associated with greater resolution of SOFA scores compared to standard feeds (5).
v. In the acute setting, high protein loads are NOT harmful to kidney function whereas they may be in patients with chronic renal failure.
vi. High levels of blood urea in patients with advanced renal failure have been shown to be safe and non-toxic if less than 107 mmol/L (6).

To underscore an important point, this discussion only applies to patients who are not receiving or about to receive dialysis. In other words, if the urea is elevated and the patient does not meet standard criteria for dialysis. This problem has been discussed extensively at the Canadian Critical Care Trials Group and with study investigators with input from our nephrology colleagues. We are relatively certain that the disproportionately elevated urea in the setting of a study patient with renal dysfunction (acute or chronic) does not represent a safely hazard and we encourage the use of study nutrients in patients with a high urea. Remember, all serious adverse events in study patients will be reviewed by a third party data safety monitoring committee.

If the patient is NOT going to be dialyzed and you are comfortable with the high urea level, continue with both the enteral and parenteral study supplements.

If the clinicians at the bedside are uncomfortable with the high urea, we want to provide them the option to withhold study supplements but in an attempt to standardize the response across the sites, we recommend the following approach:

If the patient is not going to be dialyzed (as they have not reached the standard criteria for dialysis) and if the urea ≥ 50 mmol/L, AND the clinician caring for the patient is uncomfortable with the high urea, we suggest the following approach:

1. Use lower protein enteral products to minimize protein load and check urea the next day. If urea still remains ≥ 50 mmol/L, proceed to step # 2.

2. Withhold the enteral feeds for one day. There is no evidence that withholding calories for a few days will have a negative impact in the course of a long-term ICU patient. In fact, current evidence would support the notion of restrictive or hypocaloric feeding (7). If urea drops below 45 mmol/L on subsequent days, you may resume enteral feeds. If urea still remains ≥ 50 mmol/L, proceed to step # 3.

3. Reduce the enteral study supplement by one-half the rate, from 20 ml/hr to 10 ml/hr for 24 hours and then reassess. If urea drops below 45 mmol/L on subsequent days, resume enteral study solution at full rate (20 ml/hr). If urea still remains ≥ 50 mmol/L, proceed to step # 4.

4. Advise the study pharmacist (who is unblinded) to withhold half the glutamine dose (if the patient is receiving glutamine) in the parenteral study supplements. It is important that the study coordinator and site PI remain blinded. Do not ask if the patient is receiving glutamine. If urea drops below 45 mmol/L on subsequent days, notify study pharmacist to resume full dose.
parenteral glutamine. If urea still remains ≥ 50 mmol/L, proceed to step # 5.

5. **Advise the study pharmacist (who is unblinded) to withhold ALL the glutamine dose (if the patient is receiving glutamine) in the parenteral study supplements.** If urea drops below 45 mmol/L on subsequent days, notify study pharmacist to resume full dose parenteral glutamine. If urea still remains ≥ 50 mmol/L, proceed to step # 6.

6. **Discontinue the enteral study supplement for 24 hours and then reassess.** If urea drops below 45 mmol/L on subsequent days, resume enteral study solution at full rate (20 ml/hr). If urea still remains ≥ 50 mmol/L, proceed to step # 7.

7. Start dialysis when clinically indicated and resume both enteral and parenteral study supplements. Reassess urea levels daily.

**NOTE: If at any point, enteral feeds or study supplements are withheld, the urea falls, the feeds/supplements are resumed, and the urea rises to > 50 mmol/L again, go to the beginning of the algorithm and start with step #1.**

**At any point through this algorithm, if a patient receives dialysis, return to full dose parenteral and enteral study supplements.**

3. Patients receiving both parenteral and enteral study solutions will receive approximately 750 ml/day. In patients with volume overload concerns, this may be too much fluid, can we reduce the amount or stop the study solutions?

**Response:**

If at all possible, please do not stop study supplements for volume management of study patients. The solutions are as concentrated as they can be already. If you are concerned about excessive fluid we suggest the following in the order listed below:

1. Restrict other fluids the patient is receiving and switch to a concentrated feeding formula (2cal/ml).

2. Consider using diuretics to achieve negative fluid balance.

3. If still unsuccessful with fluid management and in critical situations, consider dialysis. You may reduce the enteral study supplements to 10 ml/hr for one day to see if that helps but continue with the parenteral study supplements. Resume full rate of enteral study supplements as soon as possible.
Inclusion criteria for Renal Dysfunction

In patients without known renal disease, renal dysfunction is defined as:
- a serum creatinine $> 171$ μmol/L or
- a urine output of less than 500 ml/last 24 hours (or 80 ml/last 4 hours if a 24 hour period of observation is not available).

In patients with chronic renal failure, renal dysfunction is defined as:
- an absolute increase of $> 80$ μmol/L from baseline or pre-admission creatinine or
- a urine output of less than 500 ml/last 24 hours (or 80 ml/last 4 hours).

References
Checklist for Daily Data Collection

The checklist on the following page is a template designed to assist you with the data collection and to optimize enteral nutrition. This may be adapted to suit your needs.
Dietitian Daily Checklist

ICU Admission Date: ________________  Patient Enrollment No # ________________

Record these only once
[ ] Intramuscular (IM) only
[ ] Intravenous (IV)
[ ] Oral

Prescribed Energy Intake ___________ Kcals
Prescribed Protein Intake ___________ grams

<table>
<thead>
<tr>
<th>Study Day</th>
<th>1 (ICU admn)</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
<th>6</th>
<th>7</th>
<th>8</th>
<th>9</th>
<th>10</th>
<th>11</th>
<th>12</th>
<th>13</th>
<th>14</th>
<th>15</th>
</tr>
</thead>
<tbody>
<tr>
<td>Calories Received (Kcals)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Meeting &gt;80% of Goal calories (Y/N)?</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>If No, comment</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Protein Received (grams)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Meeting &gt;80% of Goal protein (Y/N)?</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>If No, comment</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Type of Formula received</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EN interrupted due to feeding intolerance (Y/N)?</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>If Yes to EN interrupted: Mobility agents prescribed (Y/N)?</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>If Yes to EN interrupted: Small bowel feeding tube placed (Y/N)?</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>If Yes to EN interrupted: RD review requested? (Y/N)?</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EN interrupted due to fluid/hypocaloric concerns (Y/N)?</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>If Yes, comment</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>If on PN, type of lipids received</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PN interrupted due to fluid/hypocaloric concerns (Y/N)?</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>If Yes, comment</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Study Day 1 is from ICU admission to the end of your 24 hr flowsheet.
Study Day 2 and subsequent days are the 24 hr period according to your flowsheet.
<table>
<thead>
<tr>
<th>Study Day</th>
<th>16</th>
<th>17</th>
<th>18</th>
<th>19</th>
<th>20</th>
<th>21</th>
<th>22</th>
<th>23</th>
<th>24</th>
<th>25</th>
<th>26</th>
<th>27</th>
<th>28</th>
<th>29</th>
<th>30</th>
</tr>
</thead>
<tbody>
<tr>
<td>Calories Received (Kcals)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Meeting &gt;80% of Goal calories (Y/N)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>If No, comment</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Protein Received (grams)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Meeting &gt;80% of Goal protein (Y/N)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>If No, comment</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Type of formula received</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(may select up to 3)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EN interrupted due to feeding intolerance (Y/N)?</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>If Yes to EN interrupted: Motility agents prescribed (Y/N)?</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>If Yes to EN interrupted: Small bowel feeding tube placed? (Y/N)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>If Yes to EN interrupted: RD review requested? (Y/N)?</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EN interrupted due to fluid high area concerns (Y/N)?</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>If Yes, comment</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>If on PN, type of lipids received</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PN interrupted due to fluid high area concerns (Y/N)?</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>If Yes, comment</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>